Hansoh Pharmaceutical Group's high P/E ratio may be due to expected earnings recovery. However, with lower than market growth forecast, the high P/E ratio and positive investor sentiment may not be sustainable. Current trading prices may not be reasonable without significant improvement.
Hansoh Pharmaceutical Group's strong financials and moderate growth over the past five years, along with its high rate of profit reinvestment, could potentially boost its stock value in the long-term. Analysts anticipate future earnings momentum.
$Hang Seng Index(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN-B(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$維亜生物科技(01873.HK)$...
Despite Hansoh Pharmaceutical's high P/E ratio, its minimal earnings growth and slower future growth vs. the market make its valuation questionable. Shareholders and investors may face disappointment as the high P/E isn't justified by the growth outlook.
Hansoh Pharmaceutical's commendable ROE, impressive earnings growth, and profit reinvestment strategy signal positive performance. Future payout ratio is pegged around 22% and ROE about 12%. Analysts foresee gain in the company's earnings.
Hong Kong stocks advanced, halting a six-day decline as tech companies fueled the biggest market rally in two weeks. A government report showing slower inflation in China helped boost the outlook for more monetary easing to shore up the economy. $Hang Seng Index(800000.HK)$climbed 2.6% at 19,342.98 at the local noon trading break, the most since August 25.$Hang Seng TECH Index(800700.HK)$su...
2
3
報告
Norton Symantec :
Hi, do you think HS index will up next week and hit 20k?
翰森製薬に関するコメント
As for financials, $HSBC(00005.HK)$ opened flat at $57.95. $香港証券取引所(00388.HK)$ lost 0.5% at $231.4. $友邦保険(01299.HK)$ shed 1.6% at $58.65. Chinese prope...
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $REMEGEN-B(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亜生物科技(01873.HK)$ ...
HSI Closes at 17,406, Up 7 pts; HSTI Closes at 3,854, Up 48 pts; PSBC Down over 6%; XIAOMI, LENOVO GROUP Hit New Highs
Active Heavyweights:
$中国建設銀行(00939.HK)$ closed at $4.48, down 1.8%
$テンセント(00700.HK)$ closed at $295.4, up 0.9%
$美団点評(03690.HK)$ closed at $...
Alibaba, Tencent, pharma stocks fuel best rally in two weeks as China inflation report boosts stimulus bets
$Hang Seng Index(800000.HK)$ climbed 2.6% at 19,342.98 at the local noon trading break, the most since August 25. $Hang Seng TECH Index(800700.HK)$ su...
まだコメントはありません